Evotec OAI has a long-standing relationship with Roche. In 2004, the companies signed a substantial medicinal chemistry agreement, supporting four Roche sites in the design and synthesis of high quality chemical compounds.
“The collaboration with Evotec has been very beneficial for us,” said Dr Lee Babiss, vice president of preclinical R&D at Roche. “The high quality impact of this partnership over the past few years has supported our drug discovery projects significantly, resulting in an extension of the collaboration.”
In addition to contract research partnerships, Evotec also has its own discovery program, specializing in finding new treatments for diseases of the central nervous system (CNS). The company has a number of products in late stage pre-clinical development, the most advanced of which, a potential treatment for Alzheimer’s disease, Parkinson’s disease and neuropathic pain, is expected to enter clinical trials later this year.